2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of …

F Mach, C Baigent, AL Catapano… - European heart …, 2020 - academic.oup.com
version of the Guidelines, which is freely available via the ESC and EAS websites and
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …

Inflammation in atherosclerosis—no longer a theory

P Libby - Clinical chemistry, 2021 - academic.oup.com
Background Inflammation links to atherosclerosis and its complications in various
experimental investigations. Animal studies have implicated numerous inflammatory …

Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty

L Ferrucci, E Fabbri - Nature Reviews Cardiology, 2018 - nature.com
Most older individuals develop inflammageing, a condition characterized by elevated levels
of blood inflammatory markers that carries high susceptibility to chronic morbidity, disability …

[HTML][HTML] Inflammation and cardiovascular disease: From mechanisms to therapeutics

A Alfaddagh, SS Martin, TM Leucker, ED Michos… - American journal of …, 2020 - Elsevier
Inflammation constitutes a complex, highly conserved cascade of molecular and cellular
events. Inflammation has been labeled as “the fire within,” is highly regulated, and is critical …

Lipoprotein (a), PCSK9 inhibition, and cardiovascular risk: insights from the FOURIER trial

ML O'Donoghue, S Fazio, RP Giugliano, ESG Stroes… - Circulation, 2019 - Am Heart Assoc
Background: Lipoprotein (a)[Lp (a)] may play a causal role in atherosclerosis. PCSK9
(proprotein convertase subtilisin/kexin 9) inhibitors have been shown to significantly reduce …

Update advances on C-reactive protein in COVID-19 and other viral infections

Y Luan, C Yin, Y Yao - Frontiers in immunology, 2021 - frontiersin.org
Severe coronavirus disease 2019 (COVID-19) can manifest as a viral-induced
hyperinflammation with multiorgan dysfunction. It has been documented that severe COVID …

Mendelian randomization as an approach to assess causality using observational data

P Sekula, M Fabiola Del Greco, C Pattaro… - Journal of the …, 2016 - journals.lww.com
Mendelian randomization refers to an analytic approach to assess the causality of an
observed association between a modifiable exposure or risk factor and a clinically relevant …

Mendelian randomization in cardiometabolic disease: challenges in evaluating causality

MV Holmes, M Ala-Korpela, GD Smith - Nature Reviews Cardiology, 2017 - nature.com
Mendelian randomization (MR) is a burgeoning field that involves the use of genetic variants
to assess causal relationships between exposures and outcomes. MR studies can be …

From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection

PM Ridker - Circulation research, 2016 - Am Heart Assoc
Plasma levels of the inflammatory biomarker high-sensitivity C-reactive protein (hsCRP)
predict vascular risk with an effect estimate as large as that of total or high-density …

Genome analyses of> 200,000 individuals identify 58 loci for chronic inflammation and highlight pathways that link inflammation and complex disorders

S Ligthart, A Vaez, U Võsa, MG Stathopoulou… - The American Journal of …, 2018 - cell.com
C-reactive protein (CRP) is a sensitive biomarker of chronic low-grade inflammation and is
associated with multiple complex diseases. The genetic determinants of chronic …